AOD-9604 vs Semaglutide vs Tirzepatide: Comparing Metabolic Research Peptides

AOD-9604 vs semaglutide vs tirzepatide metabolic research peptide comparison Durham Peptides Canada

These three compounds get grouped together in searches because they're all studied in the context of fat metabolism — but mechanistically, they could hardly be more different. AOD-9604 is a growth-hormone fragment studied for direct lipolysis. Semaglutide and tirzepatide are incretin peptides that act on entirely different receptors to influence appetite, insulin secretion, and energy balance. Comparing them is less about "which is best" and more about understanding three distinct approaches to the same research domain.

This article compares the three from a research perspective. For the deep dives, see What Is AOD-9604? and Semaglutide vs Tirzepatide.

The Fundamental Divide: Two Completely Different Mechanisms

The three compounds split into two mechanistic families:

Family 1 — Growth-hormone fragment (direct lipolysis):

• AOD-9604 acts directly on adipose tissue, studied for stimulating lipolysis and inhibiting lipogenesis, independent of the IGF-1 receptor.

Family 2 — Incretin peptides (appetite and insulin pathways):

• Semaglutide is a single GLP-1 receptor agonist.

• Tirzepatide is a dual GLP-1/GIP receptor agonist.

So the "vs" here is really a comparison between a fat-cell-targeting fragment and gut-hormone-mimicking peptides. They reach fat-metabolism research questions from opposite directions.

Side-by-Side Comparison

Property	AOD-9604	Semaglutide	Tirzepatide
Class	hGH fragment (176-191)	GLP-1 agonist	GLP-1/GIP dual agonist
Mechanism	Direct adipose lipolysis	Incretin (appetite, insulin)	Incretin (appetite, insulin)
Receptor(s)	IGF-1-independent; adipose pathways	GLP-1 receptor	GLP-1 + GIP receptors
Size	16 amino acids	31 amino acids	39 amino acids
Generation	GH-fragment era	Incretin gen 1	Incretin gen 2
Clinical data maturity	Mixed (6 trials, modest efficacy)	Extensive	Extensive
Durham vial	5mg (C$65)	10mg (C$64.99)	10mg (C$60)

How the Mechanisms Differ in Practice

AOD-9604 targets the fat cell itself. It's studied for mobilizing stored fat (lipolysis) and blocking new fat storage (lipogenesis) through adipose-tissue pathways, without engaging appetite or insulin signaling. It's a "downstream" approach — acting at the tissue where fat is stored.

Semaglutide and tirzepatide are "upstream" — they act on incretin receptors to influence appetite regulation, gastric emptying, and glucose-dependent insulin secretion. Their effect on body composition in research is driven substantially through reduced energy intake and improved insulin dynamics, not through direct action on fat cells. Tirzepatide adds GIP-receptor activation to semaglutide's GLP-1 mechanism, the dual-agonist advance covered in Semaglutide vs Tirzepatide.

The Clinical-Data Gap Is the Real Story

The most important practical difference is the maturity and strength of the clinical evidence:

• Semaglutide and tirzepatide have extensive, robust human clinical trial data demonstrating significant metabolic effects — they are among the most studied metabolic peptides in existence.

• AOD-9604 completed six human trials but did not demonstrate comparably strong efficacy; its research value is more mechanistic (studying isolated lipolysis) than outcome-driven.

For a researcher, this means the three compounds answer different questions. AOD-9604 is a tool for studying the lipolysis mechanism in isolation; the incretins are studied for their well-documented whole-organism metabolic effects. The incretin generation continues with the triple agonist retatrutide — see Triple Agonist Peptides Explained.

When a Researcher Would Choose Each

• Studying direct adipose lipolysis, IGF-1-independent fat metabolism → AOD-9604.

• Studying GLP-1-pathway appetite and insulin effects → semaglutide.

• Studying dual GLP-1/GIP incretin effects → tirzepatide.

• Studying triple-receptor incretin effects → retatrutide.

They aren't substitutes for one another — they're tools matched to different mechanistic questions in metabolic research.

Could They Be Studied Together?

Because AOD-9604 and the incretins act through non-overlapping mechanisms (adipose lipolysis versus incretin signaling), some research protocols examine growth-hormone-fragment and incretin approaches in combination or in parallel arms — which is why AOD-9604 appears as a "frequently paired" compound alongside semaglutide and tirzepatide. As always, combination research should rest on a clear mechanistic rationale rather than simply stacking compounds.

Quality Standards Across All Three

All three are Janoshik-verified to ≥99% purity with mass-spec identity confirmation. Metabolic readouts are sensitive to material quality, so verification matters regardless of which compound a protocol uses. See How to Read a Janoshik COAand the Lab Results page.

Frequently Asked Questions

What's the difference between AOD-9604 and semaglutide? AOD-9604 is a growth-hormone fragment studied for direct adipose lipolysis; semaglutide is a GLP-1 incretin peptide studied for appetite and insulin effects. Completely different mechanisms.

Is AOD-9604 as effective as semaglutide or tirzepatide? The incretins have far stronger and more mature human clinical data. AOD-9604's value is more mechanistic (isolated lipolysis study) than outcome-driven.

Can AOD-9604 be studied with GLP-1 peptides? Because they act through non-overlapping mechanisms, some protocols examine them in combination or parallel — though combination research should have a clear mechanistic rationale.

Which is the newest compound? Among these three, tirzepatide (dual agonist) is the newest generation; the field has since advanced to triple agonists like retatrutide.

Are all three available in Canada? Yes — Durham Peptides stocks semaglutide and tirzepatide; AOD-9604 is subject to stock availability.

Final Thoughts

AOD-9604, semaglutide, and tirzepatide all live in metabolic research, but they're three different tools for three different questions: direct adipose lipolysis versus single- and dual-incretin signaling. The incretins carry the stronger clinical record; AOD-9604 offers a distinct, IGF-1-independent lipolysis mechanism worth studying in its own right.

For the AOD-9604 deep dive, see What Is AOD-9604?; for the incretin comparison, see Semaglutide vs Tirzepatide. Browse the metabolic category at durhampeptides.ca/category/metabolic-research-peptides.

Selected Research References

1. Ng FM, Sun J, Sharma L, et al. Metabolic Studies of a Synthetic Lipolytic Domain (AOD9604) of Human Growth Hormone. Hormone Research. 2000. https://pubmed.ncbi.nlm.nih.gov/11146367/

2. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021;385(6):503-515. https://pubmed.ncbi.nlm.nih.gov/34170647/

3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/

4. Heffernan MA, Thorburn AW, Fam B, et al. Increase of Fat Oxidation and Weight Loss in Obese Mice Caused by a Modified C-Terminal Fragment of Growth Hormone (AOD-9604). International Journal of Obesity. 2001. https://pubmed.ncbi.nlm.nih.gov/11713213/

All products sold by Durham Peptides are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.